Mineralys Therapeutics (MLYS) announced that it has commenced an underwritten public offering of $175M of shares of its common stock. All of the securities to be sold in the offering are to be sold by Mineralys. Mineralys intends to use the net proceeds from the proposed offering to fund clinical development of lorundrostat, including research and development and manufacturing, and pre-commercialization activities, as well as for working capital and general corporate purposes. BofA Securities, Evercore ISI, Goldman Sachs & Co., Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- 3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
- Jefferies expects Mineralys stock to trade up following AstraZeneca data
- Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones
- Mineralys Therapeutics, Inc. Earnings Call Highlights
- Mineralys Therapeutics price target raised to $43 from $38 at BofA